Semantic Scholar uses AI to extract papers important to this topic.
Irritable bowel syndrome (IBS) is multifactorial in nature, and a wide range of therapies is available to manage symptoms of this… Expand Functional bowel disorders (FBDs) are a spectrum of disorders characterized by combinations of symptoms attributable to the lower… Expand Objectives:Eluxadoline is a mixed μ-opioid receptor (OR) and κ-OR agonist and δ-OR antagonist, approved for the treatment of… Expand Objectives:Irritable bowel syndrome with diarrhea (IBS-D) is often managed with over-the-counter therapies such as loperamide… Expand This review introduces the principles of visceral sensation and appraises the current approaches to management of visceral pain… Expand Eluxadoline is a newly approved orally administered drug used for the treatment of Irritable Bowel Syndrome with Diarrhea. It is… Expand Background Effective and safe treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea. We… Expand The effects of OATP1B1, OAT3, and MRP2 on the pharmacokinetics of eluxadoline, an oral, locally active, opioid receptor agonist… Expand Eluxadoline (Viberzi™), developed by Actavis (now Allergan), is an orally administered, first-in-class compound that functions as… Expand BACKGROUND & AIMS
Simultaneous agonism of the μ-opioid receptor and antagonism of the δ-opioid receptor can reduce abdominal pain… Expand